LCAT and familial hypercholesterolemia: Apo L1 is mainly studied in chronic kidney disease, but studies in our group showed that a coordinated decrease in HDL content of both LCAT and Apo L1 seem to predispose to the presentation of acute ischemic events in hypercholesterolemia patients [24].